Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed invasive breast cancer~* Must have known ER, PR and HER2 status~* Either, Triple Negative Metastatic Breast Cancer or~* Inflammatory Breast Cancer with any ER, PR HER2 status~* Availability of archival tissue specimen suitable for pStat3 testing~* Life expectancy of greater than 3 months~* Measurable disease by RECIST~* At least one prior chemotherapy regimen for treatment of metastatic breast cancer and/or recurrence within 12 months of completion of neoadjuvant/adjuvant chemotherapy or~* For patients with inflammatory breast cancer but no distant metastases, progression through standard neoadjuvant chemotherapy is required~Exclusion Criteria:~* Pregnant or breastfeeding~* Active brain metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib~* Clinically significant malabsorption syndrome~* Concurrent use of medications/substances that are strong inhibitors of CY3A4~* No uncontrolled intercurrent illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib-Cohort A (Type: EXPERIMENTAL): Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of \>/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
- Ruxolitinib-Cohort B (Type: EXPERIMENTAL): Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of \>/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).

Based on this trial design, predict the completion outcome and termination type (if applicable).